Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Zaid, Harras B.; Parker, William P.; Safdar, Nida; Gershman, Boris; Erwin, Patricia J.; Murad, M. Hassan; Boorjian, Stephen A.; Costello, Brian A.; Thompson, R. Houston; Leibovich, Bradley C.

doi:10.1016/j.juro.2016.07.079

Cited by 96 publications

(74 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the literature, there is a survival benefit to an aggressive approach and a complete surgical resection of the primary tumor and metastatic sites, when technically feasible, may offer the best opportunity for cure [19]. The vast majority of the patients described in the literature underwent surgical resection.…”

Section: Discussionmentioning

confidence: 99%

Isolated Splenic Metastases from Renal Cell Carcinoma 11 Years after Surgery

Romão

Horvat

Gonçalves

et al. 2019

Case Reports in Medicine

View full text Add to dashboard Cite

Splenic metastases are rare and usually occur in cases of disseminated disease. We report a case of a patient who had isolated splenic metastases with a previous history of left nephrectomy due to a renal cell carcinoma 11 years before. The aim of this report is to describe the case and review the literature of isolated splenic metastases due to renal carcinoma. This case emphasizes the importance of considering splenic metastatic disease even after many years of diagnosis of renal cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Isolated Splenic Metastases from Renal Cell Carcinoma 11 Years after Surgery

Romão

Horvat

Gonçalves

et al. 2019

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…16,17 In 2014, Dabestani and colleagues examined the evidence supporting the definitive local treatment of metastases in mRCC. 16,17 In 2014, Dabestani and colleagues examined the evidence supporting the definitive local treatment of metastases in mRCC.…”

Section: Complete Versus Incomplete Metastasectomy/ Absence Of Metastmentioning

confidence: 99%

Role of metastasis‐directed treatment in kidney cancer

Psutka

Master

2018

Cancer

View full text Add to dashboard Cite

Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive with systemic therapy alone. Definitive treatment of the metastatic deposit remains the sole potentially curative option and is a cornerstone of mRCC therapy, offering potential for both local control and palliation of tumor-related symptoms. In this review, the evidence supporting the definitive treatment of mRCC is examined and summarized, including the use of surgical metastasectomy, thermal ablation, radiotherapy, and other minimally invasive options. Multimodal approaches, including the combination of metastasectomy with novel systemic agents, are discussed. Finally, the authors review considerations for patient selection for this type of therapy and summarize available risk-stratification tools that may help guide shared decision making.

show abstract

“…However, the existing data used for this analysis may reflect a selection bias of healthy patients for complete metastasectomy and the utilization of incomplete resection for palliative, not curative, effects. Addressing this issue, Zaid et al (136) recently performed a similar meta-analysis of studies to compare complete versus incomplete metastasectomy or no surgery at all. They found comparable HRs for overall mortality in patients who had a complete metastasectomy, regardless of whether the study did or did not adjust for baseline performance status (2.59 vs. 2.16, p = 0.27, respectively).…”

Section: Metastasectomy For Rccmentioning

confidence: 99%

Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach

et al. 2017

View full text Add to dashboard Cite

The past decade has seen a rapid proliferation in the number and types of systemic therapies available for renal cell carcinoma. However, surgery remains an integral component of the therapeutic armamentarium for advanced and metastatic kidney cancer. Cytoreductive surgery followed by adjuvant cytokine-based immunotherapy (predominantly high-dose interleukin 2) has largely given way to systemic-targeted therapies. Metastasectomy also has a role in carefully selected patients. Additionally, neoadjuvant systemic therapy may increase the feasibility of resecting the primary tumor, which may be beneficial for patients with locally advanced or metastatic disease. Several prospective trials examining the role of adjuvant therapy are underway. Lastly, the first immune checkpoint inhibitor was approved for metastatic renal cell carcinoma (mRCC) in 2015, providing a new treatment mechanism and new opportunities for combining systemic therapy with surgery. This review discusses current and historical literature regarding the surgical management of patients with advanced and mRCC and explores approaches for optimizing patient selection.

show abstract

Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Cited by 96 publications

References 30 publications

Isolated Splenic Metastases from Renal Cell Carcinoma 11 Years after Surgery

Isolated Splenic Metastases from Renal Cell Carcinoma 11 Years after Surgery

Role of metastasis‐directed treatment in kidney cancer

Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach

Contact Info

Product

Resources

About